Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
BMC cancer
Hao S, Xu S, Li L, Li Y, Zhao M, Chen J, Zhu S, Xie Y, Jiang H, Zhu J, Wu M.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2022
Cancer Research
Immunology
No items found.
Key Finding
Immunofluorescence and immunohistochemical staining of xenograft tumours showed that the anti-tumour effects were associated with the inhibition of angiogenesis and the infiltration of immune cells. These clearly revealed that the anti-PD-L1/CXCR4 bispecific nanobody exerted anti-tumour efficacy in vitro and inhibited tumour growth in vivo.
Countstar Connection
Countstar (model not specified) measured migrated or invaded cell numbers in the study's cell samples during quality assessment in the 2022 BMC cancer study.
